Cargando…
Development of Vaccines against Visceral Leishmaniasis
Leishmaniasis is a neglected disease resulting in a global morbidity of 2,090 thousand Disability-Adjusted Life Years and a mortality rate of approximately 60,000 per year. Among the three clinical forms of leishmaniasis (cutaneous, mucosal, and visceral), visceral leishmaniasis (VL) accounts for th...
Autores principales: | Evans, Krystal J., Kedzierski, Lukasz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170777/ https://www.ncbi.nlm.nih.gov/pubmed/21912561 http://dx.doi.org/10.1155/2012/892817 |
Ejemplares similares
-
Leishmaniasis Vaccine: Where are We Today?
por: Kedzierski, Lukasz
Publicado: (2010) -
Determinants for the Development of Visceral Leishmaniasis Disease
por: McCall, Laura-Isobel, et al.
Publicado: (2013) -
Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine
por: Borja-Cabrera, Gulnara Patricia, et al.
Publicado: (2004) -
Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis
por: Borja-Cabrera, GP, et al.
Publicado: (2009) -
Assessment of Vaccine-Induced Immunity Against Canine Visceral Leishmaniasis
por: Moreno, Javier
Publicado: (2019)